Search Results

You are looking at 51 - 60 of 371 items for :

  • "bevacizumab" x
  • Refine by Access: All x
Clear All
Full access

Andrew H. Ko and Margaret A. Tempero

: 131 – 138 . 55 Kindler HL Friberg G Stadler WM . Bevacizumab (B) plus gemcitabine (G) in patient (pts) with advanced pancreatic cancer (PC): Updated results of a multi-center phase II trial (Abstr) . In: Proceedings of the American Society

Full access

F. Anthony Greco

cancer of unknown primary: from autopsy to microarray . Eur J Cancer 2007 ; 43 : 2026 – 2036 . 3. Hurwitz H Fehrenbacher L Novotny W . Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer . N Engl J

Full access

Mohamedtaki A. Tejani, Anna ter Veer, Dana Milne, Rebecca Ottesen, Tanios Bekaii-Saab, Al B. Benson III, Deborah Schrag, Stephen Shibata, John Skibber, Martin Weiser, Neal Wilkinson, and Steven J. Cohen

provided in Table 2 . The most common combination was a fluoropyrimidine plus oxaliplatin with or without bevacizumab (37% and 33%, respectively). The remaining patients either received fluoropyrimidine/irinotecan or single-agent fluoropyrimidine

Full access

Lirong Liu, Fangfang Hou, Yufeng Liu, Wenzhu Li, and Haibo Zhang

hypermetabolic nodules in left hilar suggestive of lung cancer with obstructive pneumonia and bone and right adrenal metastases. (B1–B3) CT after 2 cycles of carboplatin/pemetrexed with bevacizumab shows left lower lobe atelectasis aggravated with a large

Full access

Philip J. Saylor and M. Dror Michaelson

trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer . N Engl J Med 2003 ; 349 : 427 – 434 . 7 Yang JC Sherry RM Steinberg SM . Randomized study of high-dose and low-dose interleukin-2 in

Full access

Courtney P. Williams, Andres Azuero, Kelly M. Kenzik, Maria Pisu, Ryan D. Nipp, Smita Bhatia, and Gabrielle B. Rocque

categories based on the reason for discordance, including (1) therapy mismatched with hormone receptor (HR) or HER2 status, (2) HER2-targeted therapy without chemotherapy, (3) nonapproved bevacizumab use, (4) adjuvant regimens received in the metastatic

Full access

Aparna Parikh, Chloe Atreya, W. Michael Korn, and Alan P. Venook

with capecitabine and oxaliplatin plus bevacizumab after 2 months with significant functional decline. Next-generation sequencing (NGS) of the primary tumor identified HER2 amplification and we were able to obtain trastuzumab-DM1 for off-label use

Full access

Himani Aggarwal, Kristin M. Sheffield, Li Li, David Lenis, Rachael Sorg, and Rebecca Miksad

Background: PTL is a prognostic factor for mCRC. Recent data suggest PTL is also predictive of survival benefit with cetuximab (CET) and bevacizumab (BEV). This study evaluated the prognostic and predictive effect of PTL in patients with KRAS WT

Full access

Andrew D. Zelenetz

Although complex, biologic agents are key components of modern therapy in multiple disciplines, particularly oncology. However, despite the fact that biosimilars (eg, filgrastim‐sndz, bevacizumab‐awwb, trastuzumab‐dkst, rituximab-abbs) have been approved in the United States, many clinicians are poorly informed about their unique pathway for approval. At the NCCN 2019 Annual Congress: Hematologic Malignancies, Dr. Andrew D. Zelenetz, Memorial Sloan Kettering Cancer Center, outlined important issues regarding the use of biosimilars, including extrapolation, interchangeability, and naming.

Full access

Brian Vicuna and Al B. Benson III

The treatment of stage II colon cancer is a controversial issue that has persisted for the past decade. Clinicians must understand that accurate assessment of risk factors is the key to identifying patients who will benefit from treatment. Pathologic staging for colon cancer is based on the American Joint Committee on Cancer 6th edition staging system. In addition, distinct pathologic factors characterize a patient at high risk for stage II disease. More recent retrospective data suggest that molecular markers and gene expression microarrays may be valuable as prognostic and predictive tests. Unfortunately, previous research studies were not powered to properly assess efficacy in stage II disease. However, 2 recent clinical trials, National Surgical Adjuvant Breast and Bowel Project C-07 and MOSAIC, have provided more insight into defining the optimal treatment approach. With the development of the newer therapeutic agents, oxaliplatin and bevacizumab, ongoing trials such as Intergroup E5202 should help determine risk versus benefit of chemotherapy in the adjuvant treatment of stage II colon cancer.